Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells

Anti-Cancer Agents in Medicinal Chemistry, 3(4): 307-318.

Author(s): Ali Bettaieb, Laurence Dubrez-Daloz, Sophie Launay, Stephanie Plenchette, Cedric Rebe, Severine Cathelin and Eric Solary.

Affiliation: INSERM U517, IFR 100, 7 boulevard Jeanne d'Arc, 21000 Dijon, France.


Proteins of the Bcl-2 family share one or several Bcl-2 homology (BH) regions and behave as pro- or antiapoptotic proteins. Prosurvival members such as Bcl-2 and Bcl-XL are supposed to preserve mitochondrial outer membrane integrity, thus preventing the release of soluble apoptogenic molecules. Pro-apoptotic members include BH3- only proteins that act as sensors of cellular damage and initiate the death process and Bax-like proteins that act downstream of BH3-only proteins to permeabilise the mitochondrial outer membrane. Whether BH3-only proteins directly activate Bax-like proteins or prevent prosurvival members of the family from inhibiting Bax-like proteins or both remains a matter of controversy. Expression of these proteins is altered in various human tumours and this abnormal expression may contribute to oncogenesis and tumour cell resistance to anticancer drug-induced cell death. Based on these observations, prosurvival proteins are attractive intracellular targets for inducing tumour cell death or sensitising tumour cells to death induced by chemotherapeutic drugs. The use of 18-mer antisense oligonucleotides (G3139 or Genasense) targeting the first six codons of bcl-2 mRNA is currently developed in clinics with phase I studies demonstrating that thrombocytopenia may be the main dose-limiting side effect. This strategy, that efficiently decreases Bcl-2 protein expression in some tumour cells, is currently tested in phase II and phase III trials. Alternative approaches to achieve the functional knock-out of Bcl-2 include the use of either peptides mimicking the BH3 domain of Bcl-2-related proteins or more stable, non peptidic BH3 mimetics and the pharmacological modulation of the post-translational modifications of the protein.


apoptosis, cell death, bcl-2, bh3-only proteins, mitochondria, antisense oligonucleotides, bh3 mimetics.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 3
Issue Number: 4
First Page: 307
Last Page: 318
Page Count: 12
DOI: 10.2174/1568011033482396
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science